![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 22650-22656, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, April 4, 2000, and in revised form, May 15, 2000
The Rho GTPase, Cdc42, regulates a wide variety
of cellular activities including actin polymerization, focal complex
assembly, and kinase signaling. We have identified a new family of very small Cdc42-binding proteins, designated SPECs (for Small
Protein Effector of Cdc42), that
modulates these regulatory activities. The two human members, SPEC1 and
SPEC2, encode proteins of 79 and 84 amino acids, respectively. Both
contain a conserved N-terminal region and a centrally located CRIB
(Cdc42/Rac Interactive
Binding) domain. Using a yeast two-hybrid system, we found
that both SPECs interact strongly with Cdc42, weakly with Rac1, and not
at all with RhoA. Transfection analysis revealed that SPEC1 inhibited Cdc42-induced c-Jun N-terminal kinase (JNK) activation in COS1 cells in
a manner that required an intact CRIB domain. Immunofluorescence experiments in NIH-3T3 fibroblasts demonstrated that both SPEC1 and
SPEC2 showed a cortical localization and induced the formation of cell
surface membrane blebs, which was not dependent on Cdc42 activity.
Cotransfection experiments demonstrated that SPEC1 altered Cdc42-induced cell shape changes both in COS1 cells and in NIH-3T3 fibroblasts and that this alteration required an intact CRIB domain. These results suggest that SPECs act as novel scaffold molecules to
coordinate and/or mediate Cdc42 signaling activities.
The Rho GTPase, Cdc42, regulates numerous and diverse biological
activities at both the biochemical and cellular levels. Cdc42 influences membrane trafficking (1), cytokinesis (2), and kinase
signaling pathways, leading to transcriptional activation (3). Cdc42 is
best known for controlling the formation of filopodia, thin
actin-containing structures that protrude from the cell surface (4, 5).
In addition to the direct effect of Cdc42 on filopodia formation, Cdc42
can also induce cross-activation of Rac, leading to membrane ruffling
(5). This cross-talk among small GTPases may function to coordinate the
formation and dismantling of different cortical actin structures, such
as filopodia, ruffles, lamellopodia, and membrane blebs, often seen
during cell migration (6).
The ability of Cdc42 to influence these diverse activities stems from
its interactions with a large number of different kinase and non-kinase
effector proteins. Although GTP-bound Cdc42 usually interacts with
downstream effector proteins containing the conserved binding motif
called a CRIB1 domain (7),
some downstream Cdc42 effector proteins such as IQGAP do not
contain CRIB domains (8, 9). To date, six distinct families of CRIB
domain-containing Cdc42 effector proteins have been identified: PAK
(10, 11), MRCK (12), ACK (13), MLK (7, 14), WASP (15, 16) and
MSE55/BORG/CEP (17, 18). The first four of these families are
kinases. The most extensively studied Cdc42 effector proteins, the PAK
kinases (3), participate in the Cdc42-mediated cytoskeleton
rearrangements that lead to cell motility (19). PAK kinases also
activate the JNK and p38 stress kinase pathways (20-22) and are
targets of caspase-mediated proteolytic cleavage during apoptosis (23).
MRCK kinases affect actin/myosin reorganization by phosphorylating
non-muscle myosin light chain (12). Less is known about the signaling
pathways and cellular processes affected by ACK tyrosine kinases, but
they may influence cell adhesion signals (24). The fourth family, MLK
kinases, play a role in kinesin function and JNK activation (14, 25,
26).
WASP and a related protein, N-WASP, comprise a family of
non-kinase CRIB-containing proteins that function in actin
polymerization (15, 16). N-WASP regulates filopodia formation by
producing free actin filaments either via its cofilin actin-severing
domain (16) or through interactions with the actin-severing protein, profilin (27). Both WASP and N-WASP also positively regulate the ARP2/3
protein complex, which stimulates actin nucleation (28, 29). The other
non-kinase, CRIB-containing set of Cdc42 effector proteins, is the
MSE55/CEP/BORG family, which is the most structurally diverse. This
family, consisting of five members, all induce long actin-containing
cellular extensions in NIH-3T3 fibroblasts (17, 18).
With so many different Cdc42 effector proteins, many of which may
coexist in a single cell, competition and/or some mechanism for
coordination must exist to ensure that the proper Cdc42 signal is
propagated. Although many individual Cdc42 effector proteins have been
studied, little is known about how these effector proteins cooperate
and/or compete with each other, either in regulating the cytoskeleton
or in kinase signaling. Here, we have identified a novel family of
Cdc42 effector proteins that may play a role in this higher level of
coordination. This new family, designated SPEC (for Small
Protein Effector of Cdc42) has two
human members, SPEC1 and SPEC2. Both are very small and are highly
conserved. SPECs appear to have multifaceted activities, of which some
are independent of Cdc42 binding and some are dependent on Cdc42
binding. For instance, expression of SPECs in NIH-3T3 fibroblasts
induced membrane blebbing. SPEC-induced blebbing did not require Cdc42 activity because blebbing still occurred with a CRIB domain mutant of
SPEC or in the presence of dominant negative Cdc42. SPEC1 blocked both
Cdc42-induced JNK activity and altered Cdc42-induced morphology changes
in COS1 cells and in NIH-3T3 fibroblasts in a manner that required an
intact CRIB domain and, thus, was dependent on Cdc42 binding. Together
these results suggest that SPECs act as novel scaffold molecules to
coordinate and/or mediate Cdc42 signaling activities.
Identification and Cloning of SPECs--
Clones of SPEC1 were
identified from a TBLASTN search of the expressed sequence tag (EST)
data base at the National Center for Biotechnology Information
(NCBI) using the 16-amino acid CRIB core sequence of MSE55 (7)
(ISHPLGDFRHTMHVGR) as a query. Several of these human EST clones were
obtained from the I.M.A.G.E. consortium (clone ID numbers: 257442, 139233, 160147) and sequenced on an Applied Biosystem 377 DNA
sequencer. The GenBankTM accession number of SPEC1 is AF187845.
Furthermore, EST clones for human and mouse SPEC1 are quite abundant
and are represented by the NCBI Unigene identifiers Hs.22065 and
Mm.28189, respectively.
Additional TBLASTN searches of the non-redundant nucleotide data base
using the amino acid sequence of SPEC1 as query identified three well
separated DNA sequences that if transcribed as a single mRNA and
properly spliced might encode a second SPEC-like protein. Two
adapter-primers, 5'-GAGGGATCCAGTGAATTCTGGTTGTGT-3' and
5'-GAGCTCGAGCTATCCCGCCTTCGTATC-3', derived from these genomic sequences
and corresponding to each end of the putative coding sequence, were
synthesized. These two primers were used in reverse transcription-PCR
with MCF-7 breast cancer cell RNA as template. After PCR, an
approximately 250-base pair PCR fragment was obtained, cut with
BamHI/XhoI, and subcloned into the
BamHI-XhoI site of pCAF2, a mammalian expression
vector (17). DNA sequencing revealed that the nucleotide sequence of this PCR product was, as expected, derived from the three different 5q31 genomic fragments and encodes a protein, designated SPEC2, that
was quite similar to SPEC1. SPEC2 has GenBankTM accession number
AF189692.
Yeast Two-hybrid Assays--
The yeast two-hybrid assay was
performed in the Y190 yeast strain using the pYTH GAL4 DNA binding
domain yeast vector and pACT-II GAL4 activation domain yeast vectors
(30). cDNAs for SPEC1 (amino acids 2-79) or SPEC2 (amino acids
2-84) were subcloned downstream of the GAL4 DNA binding domain in
pYTH-9, and integrated strains were generated as described (30).
Deletion mutants of SPEC1 consisting of amino acids 2-27 (SPEC1-del1)
or amino acids 48-79 (SPEC1-del2) were constructed in the same way.
Wild type and activated mutants of Cdc42, Rac, and Rho were subcloned
downstream of the GAL4 activation domain in pACT-II. Protein-protein
interactions were detected by assaying for Mammalian Expression Vectors for SPEC1, SPEC2, and
Mutants--
The coding sequence of SPEC1 was amplified by PCR
from the I.M.A.G.E. cDNA clone (ID 22978) using the two primers
5'-GAGGGATCCAGTGAATTTTGGCACAAAC-3' and
5'-GAGCTCGAGCTATAAGCCCCTAGAATTG-3'. This PCR product was then subcloned in-frame into the BamHI-XhoI sites
downstream of an N-terminal myc epitope-tagged pcDNA-III
(Invitrogen) or an N-terminal FLAG epitope-tagged pCAF2 mammalian
expression vector. An additional C-terminal myc epitope-tagged SPEC1
construct was constructed in the pcDNA-III mammalian expression
vector. Untagged SPEC1 constructs were also constructed using the
bicistronic enhanced green fluorescent protein (EGFP) vector
(CLONTECH). The integrity of all constructs was
confirmed by DNA sequencing.
Several SPEC1 mutant constructs were generated from the epitope-tagged
constructs by using SPEC1 sequence-specific oligonucleotides and the
QuickChange mutagenesis kit (Stratagene). Four single or multiple SPEC1
point mutants containing alanine substitutions in the N terminus
(SPEC1-C10A,C11A), the CRIB domain (SPEC1-H38A and
SPEC1-P35A,H38A,H41A) or in the C terminus (SPEC1-Q62A,K64A) were
constructed. The integrity of all constructs was confirmed by DNA
sequencing. All of these mutants and their parent constructs had
approximately similar levels of expression in transfected cells as
judged by immunofluorescence.
JNK Kinase Assays--
COS1 cells were used to examine whether
SPEC influenced JNK kinase activation using ATF-2 as substrate as
described (31). Equal amounts of DNA were used in each transfection.
Immunofluorescence--
Immunofluorescence of NIH-3T3
fibroblasts was performed essentially as described (17) except that
LipofectAMINE Plus (Life Technologies, Inc.) was used as the
transfection reagent. Twenty-four hours post-transfection, NIH-3T3
fibroblasts were fixed and permeabilized on glass coverslips coated
with polylysine. Coverslips were stained with the myc and FLAG
anti-epitope primary antibodies including mouse anti-FLAGTM M2
(Sigma), mouse anti-c-myc monoclonal antibody (Sigma), and polyclonal
anti-FLAGTM/Octaprobe antibody (Santa Cruz Biotechnology).
Fluorescein-conjugated goat anti-mouse IgG (Rockland Immunochemicals,
Gilbertsville, PA), Texas Red anti-mouse (Jackson ImmunoResearch
Laboratories, Inc.), and FITC-conjugated goat-anti-rabbit (Rockland
Immunochemicals) were used as secondary antibodies. Texas
Red-conjugated Phalloidin (Sigma) was used to stain F-actin. Nuclear
and phosphotidylserine staining was also performed using 4,6-diamidino-2-phenylindole (Sigma) and annexin-V (Trevigen, Inc.), respectively.
Blebbing cells were quantified in vector alone and in SPEC-ransfected
cells 24 h post-ransfection. Cells with two or more outpouchings
were scored as positive for membrane blebbing. Fifty to one hundred
cells were scored from each of at least three independent transfections. A Zeiss Photomicroscope III equipped with a Planapo 63X/1.4 NA phase 3 objective was used, and photographs were taken with
Kodak TMAX400 film using a Nikon N6006 camera.
Identification of Genes for SPEC1 and SPEC2--
Most known
Cdc42-inding proteins contain a conserved core domain, the CRIB domain
(7). We looked for additional proteins that might bind Cdc42 by
searching the human EST data base for sequences similar to the CRIB
domain of the non-kinase Cdc42 effector protein MSE55/CEP1 (17) and
identified many cDNAs encoding the same small protein. The DNA
sequences of several independent human clones comprising a contig
spanning 1.8 kilobases each showed an open reading frame of 79 amino
acid residues, which we designated SPEC1 (Fig.
1). These cDNAs encoding the SPEC1
protein contained a Kozak consensus sequence and an upstream in-frame
stop codon and did not encode any proteins longer than SPEC1. A second
human SPEC family member, designated SPEC2, was identified by searching the non-redundant GenBankTM data base. This search identified three short separated genomic regions from chromosome 5q31, spanning at least
28 kilobases (GenBankTM accession numbers AC001489 and AC001223) that
if transcribed and properly spliced would encode a second SPEC-like
protein. To clone the SPEC2 cDNA sequence, primers were designed
for the two extreme ends of the genomic regions and used in reverse
transcription-PCR. This approach yielded a 250-base pair PCR fragment
containing an open reading frame of 84 amino acids (Fig. 1). Comparison
of this sequence with 5q31 genomic sequences confirmed that the
full-length SPEC2 protein was encoded in three exons spanning at least
28 kilobases.
In addition to the human SPEC1 and SPEC2 proteins, we have also
identified both SPEC1 and SPEC2 homologs in other organisms. We have
identified SPEC1 homologs from mouse (GenBankTM AI472516) and chicken
(GenBankTM AI981286) that are 96 and 83% identical to SPEC1 at the
amino acid level, respectively (Fig. 1). We have also identified SPEC2
homologs from mouse (GenBankTM AW061198), rat (GenBankTM AA944330),
Drosophila (AA820736), and ascidian (Halocynthia
roretzi; GenBankTM AV382466) (Fig. 1). Identification of the SPEC
proteins in such diverse organisms suggests their function may be
conserved through evolution.
SPECs Represent a Novel Family of Cdc42-binding
Proteins--
SPEC1 and SPEC2 represent two members of a new protein
family that are 76% similar over their entire length (Fig. 1) and
encode proteins with predicted molecular masses of 7.9 kDa and 8.4 kDa, respectively. Both SPECs contain a highly conserved N-terminal region
and a typical CRIB domain. The CRIB domains of the SPECs extend beyond
the CRIB core sequence and contain the consensus sequence
DR(S/T)MIGEPXNFVHXXHAGSGD/EAXXG, where A represents an aliphatic amino acid, and bold
letters identify the CRIB core (Fig. 1). In the C terminus of both
proteins there is a relatively small conserved sequence containing the
nine-amino acid consensus sequence, (V/I)Q(E/N)QM(R/Q)SKG (Fig. 1).
This region may be part of an extended high affinity Cdc42 binding site
(32, 33).
CRIB-dependent Cdc42 Binding by SPECs--
Since
proteins containing a consensus CRIB domain will bind Cdc42 and/or Rac
(7), we predicted that both SPEC1 and SPEC2 also would interact with
Cdc42 and/or Rac. We tested this prediction in a yeast two-hybrid
system. Both SPEC1 and SPEC2 interacted strongly with a constitutively
activated mutant of Cdc42 (Cdc42-Q61L), weakly with an activated mutant
of Rac1 (Rac1-Q61L), and not at all with an activated mutant of RhoA
(RhoA-Q63L) using both the SPEC1 Expression Inhibits Cdc42-induced JNK Activity--
Since a
variety of studies have shown both that Cdc42 (31, 34) and some Cdc42
effector proteins (14, 20-22, 26) can activate JNK activity, we tested
SPEC1 and several SPEC1 mutants for their effect on Cdc42-induced JNK
activation. First, an expression construct of human SPEC1 carrying an
N-terminal FLAG epitope tag was transfected into NIH-3T3 fibroblasts,
and its expression was analyzed by Western blotting using a monoclonal
antibody against the N-terminal FLAG epitope tag. Using this approach,
SPEC1 was detected in lysates as an ~8 kDa species (data not shown),
of which about 1 kilobase is contributed by the epitope tag. Second, several SPEC1 mutants were constructed, including two CRIB mutants and
a C-terminal double mutant. The two CRIB mutants, SPEC1-H38A and
SPEC1-P33A,H38A,H41A, contain alanine substitutions within critical
contact sites known to be involved in Cdc42 binding (33, 34). The third
mutant, SPEC1-Q62A,K66A, contained mutations within the nine-amino acid
region conserved between both SPEC proteins that might be part of an
extended high affinity Cdc42 binding site. COS1 cells were
cotransfected with the expression vectors for GFP (control) or
Cdc42-Q61L, hemagglutinin (HA) epitope-tagged JNK, and FLAG-tagged
SPEC1 constructs. After 24 h, transiently expressed HA-JNK was
isolated by immunoprecipitation and used for in vitro kinase
assays. All SPEC1 constructs tested were not able to stimulate JNK
activity on their own (Fig.
3A). Expression of Cdc42 with
HA-JNK stimulated kinase activity (Fig. 3, A and B). Cotransfection of cells with wild-type SPEC1
significantly reduced the Cdc42-induced JNK activation (Fig. 3,
A and B). In contrast, SPEC1-P33A,H38A,H41A or
SPEC1-Q62A,K66A were markedly less effective at blocking Cdc42-induced
JNK activation (Fig. 3, A and B). In addition, a
similar failure to block Cdc42-induced JNK activation was also observed
with the single CRIB domain mutant (data not shown). Although we cannot
rule out the possibility that our overexpression studies have resulted
in abnormally high levels of SPEC1, which may nonspecifically inhibit
Cdc42 signaling pathways, these results may also suggest that SPEC1
modulates JNK activity by binding or sequestering Cdc42 through a
CRIB-dependent interaction.
SPEC1 Expression Inhibits Cdc42-induced Morphological Changes in
COS1 Cells--
We next examined the cellular distribution of
epitope-tagged SPEC1 expression by immunofluorescence. In COS1 cells,
SPEC1 showed diffuse cytoplasmic localization (Fig.
4B). Additionally, SPEC-expressing cells did not show altered actin structures or cell
morphology (data not shown). We next determined whether SPEC1 influenced Cdc42 function when co-expressed with Cdc42. COS1 cells expressing the constitutively active Cdc42-Q61L mutant exhibited a
widely spread and flattened phenotype with some filopodia (Fig. 4,
A and B). Cotransfection of SPEC1 with Cdc42-Q61L
resulted in cells that were more elevated and much less spread than
cells expressing Cdc42-Q61L alone (compare Fig. 4, C and
D with A) or untransfected cells (data not
shown). In contrast to what was seen with wild-type SPEC1, cells
coexpressing Cdc42-Q61L and the CRIB domain mutant (SPEC1-H38A)
resembled cells transfected with Cdc42-Q61L alone (compare Fig. 4,
E and F with A). These results suggest
that SPEC1 modifies Cdc42 function. In these experiments, SPEC1 appears
to alter Cdc42 activity by binding to it via the CRIB domain. These
results suggest that SPECs may function to block the interaction of
Cdc42 with other effector proteins, although we cannot rule out the
possibility that the observed blocking activity was due to
overexpression of SPEC1 protein.
SPEC Expression Induces Non-apoptotic Blebbing in NIH-3T3
Fibroblasts--
Since SPEC1 expression did not noticeably alter the
morphology of COS1 cells, we studied the effects of SPEC1 expression in NIH-3T3 fibroblasts. In NIH-3T3 fibroblasts, SPEC1 displayed a predominant cortical localization (Fig.
5A), and frequently, these transfected cells showed extensive membrane blebbing (Fig.
5A). F-actin stained strongly within the periphery of the
blebs but not within the blebs (Fig. 5B). Expression of
SPEC2 also showed the same cortical localization, membrane blebbing,
and F-actin staining phenotype (Fig. 5, C and D).
A similar pattern of cortical staining and blebbing were observed with
a myc epitope tag located either at the N or C terminus of SPEC1 and
using a 20-fold range of plasmid concentrations (100 ng to 2 µg; data
not shown). Although this SPEC-induced membrane blebbing is
morphologically similar to the membrane blebbing associated with
apoptosis, there is no functional association of the SPEC-induced
blebbing with apoptosis. That is, neither nuclear condensation
following 4,6-diamidino-2-phenylindole staining of nuclei nor annexin-V
positive staining, a marker for phosphotidylserine flipping in the
membrane, was observed in these transfected cells (data not shown).
Quantitatively, membrane blebbing was observed in 40-60% of the FLAG
epitope-tagged SPEC1 transfected cells but only in about 5% of cells
expressing the vector-alone control (Fig.
6). We also used a bicistronic expression
vector expressing both SPEC1 and EGFP from the same vector to rule out
the possibility that the epitope tags might influence SPEC function.
About 40% of the cells expressing the bicistronic SPEC1 construct
showed a blebbing phenotype, whereas only 10% were blebbing with the
EGFP-alone vector (Fig. 6). Taken together, these results demonstrate
that expression of SPECs, whether epitope-tagged or untagged, leads to
membrane blebbing in NIH-3T3 fibroblasts.
SPEC1-induced Blebbing Is Independent of Cdc42 Activity--
To
determine whether any of the three conserved regions in SPECs (see Fig.
1) are necessary for SPEC1-induced membrane blebbing, we examined the
phenotype of cells transfected with various SPEC1 mutants. An
additional N-terminal mutant, SPEC1-C10A,C11A was created within two
conserved cysteine residues because of the potential role of these
residues in lipid modification or protein interactions. Using cell
counting it was found that both the positive and negative controls gave
the expected results: approximately 44% of N-terminal FLAG-tagged
SPEC1-transfected cells blebbed, as compared with only 4% using a
vector-alone control (Fig. 7). The
C-terminal double point mutant, SPEC1-Q62A,K66A, had no effect on the
level of blebbing (Fig. 7). In contrast, the cells expressing the
N-terminal mutant (SPEC1-C10A,C11A), which showed a similar level of
expression and cortical localization, produced the blebbing phenotype
in only 20% of the transfected cells (Fig. 7). Single or triple amino
acid substitutions within the CRIB domain of SPEC1 resulted in somewhat
fewer blebs, although they still produced significantly more than the
negative controls (30% versus 4%; Fig. 7). Additional
studies expressing a dominant negative mutant of Cdc42 (Cdc42-T17N)
alone did not induce membrane blebbing, and co-expression with SPEC1
did not block membrane blebbing (data not shown). These results support
a model whereby SPEC1-induced blebbing does not occur through classical
Cdc42-effector interactions and suggest that SPEC1 may act
independently of Cdc42 or perhaps upstream of Cdc42 to induce membrane
blebbing. These data also confirm that SPEC-induced membrane changes
are not directly due to sequestration of Cdc42.
SPEC1 Expression Alters Cdc42-induced Changes in Cellular
Morphology in NIH-3T3 Fibroblasts--
To more clearly define the
relationship between Cdc42 activity and SPECs, we tested the effect of
SPEC1/Cdc42 co-expression in NIH-3T3 fibroblasts. In these fibroblasts,
expression of Cdc42L61 resulted in cells that predominantly exhibited a
membrane ruffling phenotype, possibly through activation of Rac
signaling. We then cotransfected SPEC1 or the SPEC1-CRIB mutants
(SPEC1-H38A or SPEC1-P33A,H38A,H41A) with constitutively active Cdc42
and quantified by cell counting the number of transfected cells showing
a ruffling phenotype. Expression of a constitutively active Cdc42
mutant (Cdc42-Q61L), but not wild type Cdc42 (data not shown), in
NIH-3T3 fibroblasts induced marked membrane ruffling in 52% of the
transfected cells (Fig. 8, A
and B). Co-transfection of SPEC1 blocked ruffling in all but
5% of the transfected cells and increased the number of blebbing cells
(Fig. 8, C and D). Coexpression of the SPEC-H38A mutant resulted in 34% of the cells showing a membrane ruffling phenotype (Fig. 8, E and F) and resembled cells
transfected with Cdc42 alone (compare Fig. 8, A and
B, with E and F). Similar results were
also obtained with the SPEC1-P33A,H38A,H41A CRIB mutant (data not
shown). It is also worthy to note that in these cotransfections experiments, SPEC1 and Cdc42 proteins appear to localize to similar regions within the cells, suggesting that SPECs and Cdc42 may be
contained within the same signaling complexes (Fig. 8). As with COS1
cells, these transfections demonstrate that SPEC1 expression led to an
altered Cdc42-induced morphology and that this alteration is dependent
on the presence of an intact CRIB domain.
Here we identify a new family of proteins capable of binding to
Cdc42, designated SPECs, found in many eukaryotic species. The two
human members, SPEC1 and SPEC2, are the smallest known GTPase-binding
proteins. Their small size may explain why they were not detected in
previous biochemical screens based on binding to Cdc42. Overexpression
of different combinations of SPECs, SPEC mutants, and Cdc42 showed that
SPEC expression inhibited Cdc42-induced JNK activity. SPEC
overexpression also altered or reversed the cellular morphologies
produced when Cdc42 is overexpressed in COS1 cells and in NIH-3T3
fibroblasts. The membrane blebbing induced by SPEC overexpression in
NIH-3T3 fibroblasts was not observed in COS1 cells, possibly due to
quantitative differences in expression levels of SPEC proteins between
the two cell types. Nevertheless, these results show that SPECs are
capable of modifying Cdc42-dependent signaling at both the
biochemical and cellular levels in a CRIB-dependent manner.
SPEC binding could prevent the interaction of Cdc42 with other effector
proteins. Consistent with this model, a polypeptide containing just the
CRIB domain of PAK can effectively inhibit Cdc42 activation of JNK
kinase (34) and block transcriptional activation (35), whereas a
polypeptide containing the CRIB domain of ACK-1 can act as a
Cdc42-specific inhibitor, blocking v-Ha-Ras-induced transformation
(36).
However, we do not know if the specific biochemical and biological
effects observed here with overexpressed SPECs reflect the normal
function of these small proteins. In particular, SPEC overexpression
induced membrane blebbing in NIH-3T3 fibroblast that was not blocked by
dominant negative Cdc42 expression. Despite these findings, it is still
possible that SPECs function in Cdc42-induced morphological changes,
since a dominant negative approach may not rescue the abnormal
morphology of overexpressed SPEC protein. Furthermore, various studies
have shown that non-apoptotic membrane blebs function normally in cell
spreading (37, 38) and locomotion (39-41). Mechanistically, membrane
blebs occur at sites where the cortical actin is locally depolymerized
or detached from the membrane (38, 40, 41) via alteration in cortical
actin-binding proteins (40), myosin light chain kinase activity (42,
43), and/or focal complex assembly (43). Thus, it is tempting to
speculate that SPECs may function as classical Cdc42 effector proteins
by altering the normal signaling pathways leading to actin, myosin, and/or focal complex assembly.
The existence of small proteins that bind important signaling molecules
is not unique to Cdc42. Recently, an 18-kDa protein, A-kinase anchoring
protein-18 (AKAP18), was found to function as a scaffold protein,
coupling protein kinase A signaling to calcium and sodium channels
(44-46). Interestingly, AKAP18 and SPECs share many structural and
functional similarities. First, both are small proteins: AKAP18, SPEC1,
and SPEC2 are 81, 79, and 84 amino acids long, respectively. Second,
both bind their ligands, protein kinase A or Cdc42, through their
central binding regions. Third, both localize to the plasma membrane.
Although the membrane localization of AKAP18 involves lipid
modification of the N terminus, we have not yet identified the region
required to target SPECs to the membrane in NIH-3T3 fibroblasts. Based on these similarities, we speculate that SPECs, like AKAP18, may function as scaffolding molecules to recruit other signaling proteins to Cdc42 complexes. Future studies are aimed at identifying such SPEC-binding partners.
*
This work was supported by Susan G. Komen Foundation Grant
9851 (to P. D. B.) and a Department of Defense (DOD) breast
cancer pre-doctoral fellowship (to D. M. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF187845 and AF189692.
¶
To whom correspondence should be addressed: Rm. EG16, New
Research Bldg., Lombardi Cancer Center 3970 Reservoir Rd. NW,
Georgetown University Medical Center, Washington, D. C. 20007. Tel.:
202-687-1444; Fax: 202-687-7505; E-mail:
burbelpd@gunet.georgetown.edu.
Published, JBC Papers in Press, May 16, 2000, DOI 10.1074/jbc.M002832200
The abbreviations used are:
CRIB, Cdc42/Rac
interactive binding domain;
AKAP, A-kinase anchoring protein;
EST, expressed sequence tag;
JNK, c-Jun N terminal kinase;
SPEC, small
protein effector of Cdc42;
EGFP, enhanced green fluorescent protein;
PCR, polymerase chain reaction;
FITC, fluorescein isothiocyanate;
contig, group of overlapping clones;
HA, hemagglutinin.
SPECs, Small Binding Proteins for Cdc42*
,
¶
Lombardi Cancer Center, Department of
Oncology, Georgetown University Medical Center, Washington, D. C. 20007 and § Oral and Pharyngeal Cancer Branch, NIDCR,
National Institutes of Health, Bethesda, Maryland 20892
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase activity
in a filter assay or by growth on nutrient agar plates lacking
histidine (30).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (37K):
[in a new window]
Fig. 1.
The SPEC protein family. Alignment of
full-length human SPEC1 and SPEC2 amino acid sequences. ESTs
corresponding to mouse SPEC1 (AI472516), chicken SPEC1 (AI981286), and
Xenopus SPEC2 (AW644132) and Drosophila SPEC2
(AAF51990) are also shown. Vertical lines identify identical
residues, colons represent conservative substitutions, and
the numbers at the ends represent the total number of amino
acid residues. The CRIB consensus is shown (7), and sequences matching
this consensus sequence are shown in bold letters. Human
SPEC1 and SPEC2 sequences are available from GenBankTM under accession
numbers AF187845 and AF189692, respectively.
-galactosidase filter assay (Fig.
2) and growth on selective media (data
not shown). Although interaction of SPECs with wild type Cdc42 and wild
type Rac1 was not observed, our results are consistent with yeast
two-hybrid experiments using other CRIB-containing Cdc42 effector
proteins, such as WASP (30). Additionally, SPEC CRIB deletion mutants
retaining either the N terminus (SPEC1-del1; amino acids 2-27) or the
C terminus (SPEC1-del2; amino acids 48-79) were unable to bind to an
activated Cdc42 mutant (Fig. 2). Collectively, these results
demonstrate that SPECs can interact with Cdc42 in a
CRIB-dependent fashion and suggest that SPECs may function
normally in Cdc42-dependent signaling.

View larger version (6K):
[in a new window]
Fig. 2.
SPEC1 and SPEC2 interact with Cdc42 in yeast
two-hybrid assays. pYTH9 GAL4-DNA binding constructs were
generated for SPEC2, SPEC1, or deletions of SPEC1 and then integrated
into Y190 yeast cells. These yeast strains were used as host cells for
transformations with pACT-GAL4 activation constructs to test
interactions with Rho GTPases. The strength of the interaction was
classified by the time taken for colonies to turn blue in the
-galactosidase filter assay: +++, <25 min; ++, 25-50 min; +50-100
min;
, no color change by 100 min; and ND, not
determined.

View larger version (19K):
[in a new window]
Fig. 3.
SPEC1 inhibits Cdc42-induced JNK
activation. COS1 cells were transfected with expression vectors
for GFP (control) or activated Cdc42 mutant (Cdc42-QL61), HA-tagged
JNK, and different FLAG-tagged SPEC1 constructs. Following
immunoprecipitation, JNK activity was assayed using ATF-2 as substrate
(A). Similar results were obtained in three independent
experiments. This assay was normalized by Western blot analysis using
anti-HA immunoprecipitates from the cellular lysates and immunodetected
with JNK antisera as described under "Experimental Procedures."
Results are the averages ± S.E. of three experiments.
WT, wild type.

View larger version (93K):
[in a new window]
Fig. 4.
SPEC1 alters Cdc42 activity in COS1
cells. COS1 cells were transfected with myc-tagged Cdc42-Q61L and
processed for indirect immunofluorescence at 24 h
post-transfection using monoclonal antibodies specific for the myc
epitope tag followed by either Texas Red-conjugated goat anti-mouse
antibodies or FITC-conjugated goat anti-mouse antibodies (A,
C, and E). Cells transfected with myc-tagged
Cdc42-Q61L alone were co-stained for F-actin (B). Cells
cotransfected with either FLAG-tagged wild-type SPEC1 (D) or
FLAG-tagged SPEC1-H38A (F) were processed for indirect
immunofluorescence using a polyclonal FLAGTM/octaprobe antibody
followed by FITC-labeled goat anti-rabbit secondary antibodies. The
morphology of the COS1 cells transfected with Cdc42-Q61L resemble those
cotransfected with the SPEC1-H38A mutant (compare A with
E). Bar, 10 µm.

View larger version (110K):
[in a new window]
Fig. 5.
SPEC1 and SPEC2 induce membrane blebbing in
NIH-3T3 fibroblasts. N-terminal FLAG epitope-tagged SPEC1
(A and B) or N-terminal FLAG epitope-tagged SPEC2
(C and D) constructs were transfected into
NIH-3T3 fibroblasts. The cells were fixed 24 h after transfection
and processed for indirect immunofluorescence using an anti-FLAG
monoclonal antibody followed by FITC-conjugated goat anti-mouse
secondary antibody to detect SPEC1(A) and SPEC2
(C) protein expression. Cells were co-stained for F-actin
using Texas Red conjugated-phalloidin (B and D).
Bar, 10 µm.

View larger version (22K):
[in a new window]
Fig. 6.
Quantitative analysis of the effect of tagged
and untagged SPEC1 on blebbing. NIH-3T3 fibroblasts were
transfected, fixed, and processed for indirect immunofluorescence.
NIH-3T3 fibroblasts showing at least two membrane blebs were scored as
positive for blebbing as described under "Experimental Procedures";
values indicate mean and S.D. V, pCAF2 vector alone;
SPEC1, pCAF2-SPEC1; EGFP, EGFP vector alone;
SPEC1-EGFP, bicistronic SPEC1-EGFP vector.

View larger version (24K):
[in a new window]
Fig. 7.
Activity of different SPEC1 mutants in
inducing membrane blebbing. Wild-type SPEC1 and different SPEC
mutants were transfected into NIH-3T3 fibroblasts. At 24 h
post-transfection, cells were fixed, processed for indirect
immunofluorescence, and counted for blebbing as described above in the
legend to Fig. 6; values indicate the mean and S.D. V, pCAF2
vector alone; SPEC1, pCAF2-SPEC1; C10A,C11A,
pCAF2-SPEC1-C10A,C11A; H38A, pCAF2-SPEC1-H38A;
Q62A,Q66A, pCAF2-SPEC1-Q62A,Q66A.

View larger version (87K):
[in a new window]
Fig. 8.
SPEC1 alters Cdc42-induced cell shape
changes. NIH-3T3 fibroblasts were transfected with myc-tagged
Cdc42-Q61L and processed for indirect immunofluorescence at 24 h
post-transfection using monoclonal antibodies specific for the myc
epitope tag followed by either Texas Red-conjugated goat anti-mouse
antibodies or FITC-conjugated goat anti-mouse antibodies (A,
C, and E). Cells transfected with myc-tagged
Cdc42-Q61L alone were co-stained for F-actin (B). Cells
cotransfected with either FLAG-tagged wild type SPEC1 (D) or
FLAG-tagged SPEC1-H38A (F) were processed for indirect
immunofluorescence using a polyclonal FLAGTM/octaprobe antibody
followed by FITC-labeled goat anti-rabbit secondary antibodies. The
morphology of the NIH-3T3 fibroblasts transfected with Cdc42-Q61L
resemble those cotransfected with the SPEC1- CRIB mutant (compare
A with E). Bar, 10 µm.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kroschewski, R,
Hall, A,
and Mellman, I.
(1999)
Nat. Cell Biol.
1,
8-13
2.
Drechsel, D. N.,
Hyman, A. A,
Hall, A,
and Glotzer, M.
(1997)
Curr. Biol.
7,
12-23
3.
Johnson, D. I.
(1999)
Microbiol. Mol. Biol. Rev.
63,
54-105
4.
Kozma, R.,
Ahmed, S.,
Best, A.,
and Lim, L.
(1995)
Mol. Cell. Biol.
15,
1942-1952
5.
Nobes, C. D.,
and Hall, A.
(1995)
Cell
81,
53-62
6.
Stossel, T. P.
(1993)
Science
260,
1086-1094
7.
Burbelo, P.,
Drechsel, D.,
and Hall, A.
(1995)
J. Biol. Chem.
270,
29071-29074
8.
Hart, M. J.,
Callow, M. G.,
Souza, B.,
and Polakis, P.
(1996)
EMBO J.
15,
2997-3005
9.
Kuroda, S.,
Fukata, M.,
Kobayashi, K.,
Nakafuku, M.,
Nomura, N.,
Iwamatsu, A.,
and Kaibuchi, K.
(1996)
J. Biol. Chem.
271,
23363-23367
10.
Manser, E.,
Leung, T.,
Salihuddin, H.,
Zhao, Z.,
and Lim, L.
(1994)
Nature
367,
40-46
11.
Martin, G. A.,
Bollag, G.,
McCormick, F.,
and Abo, A.
(1995)
EMBO J.
14,
1970-1978
12.
Leung, T.,
Chen, X.,
Tan, I.,
Manser, E.,
and Lim, L.
(1998)
Mol. Cell. Biol.
18,
130-140
13.
Manser, E.,
Leung, T.,
Salihuddin, H.,
Tan, L.,
and Lim, L.
(1993)
Nature
363,
364-367
14.
Teramoto, H.,
Coso, O. A.,
Miyata, H.,
Igishi, T.,
Miki, T.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
27225-27228
15.
Symons, M.,
Derry, J. M.,
Karlak, B.,
Jiang, S.,
Lemahieu, V.,
McCormick, F.,
Francke, U.,
and Abo, A.
(1996)
Cell
84,
723-734
16.
Miki, H.,
Sasaki, T.,
Takai, Y.,
and Takenawa, T.
(1998)
Nature
391,
93-96
17.
Burbelo, P. D.,
Snow, D. M.,
Bahou, W.,
and Spiegel, S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9083-9088
18.
Joberty, G.,
Perlungher, R. R.,
and Macara, I. G.
(1999)
Mol. Cell. Biol.
19,
6585-6597
19.
Sells, M. A.,
Boyd, J. J.,
and Chernoff, J.
(1999)
J. Cell Biol.
145,
837-849
20.
Bagrodia, S.,
Derijard, B.,
Davis, R. J.,
and Cerione, R. A.
(1995)
J. Biol. Chem.
270,
27995-27998
21.
Zhang, S.,
Han, J.,
Sells, M. A.,
Chernoff, J.,
Knaus, U. G.,
Ulevitch, R. J.,
and Bokoch, G. M.
(1995)
J. Biol. Chem.
270,
23934-23936
22.
Brown, J. L.,
Stowers, L.,
Baer, M.,
Trejo, J.,
Coughlin, S.,
and Chant, J.
(1996)
Curr. Biol.
6,
598-605
23.
Rudel, T.,
and Bokoch, G. M.
(1997)
Science
276,
1571-1574
24.
Yang, W.,
Lin, Q.,
Guan, J. L.,
and Cerione, R. A.
(1999)
J. Biol. Chem.
274,
8524-8530
25.
Tibbles, L. A.,
Ing, Y. L.,
Keifer, F.,
Chan, J.,
Iscove, N.,
Woodgett, J. R.,
and Lassam, N. J.
(1996)
EMBO J.
15,
7026-7035
26.
Nagata, K.,
Puls, A.,
Futter, C.,
Aspenstrom, P.,
Schaefer, E.,
Nakata, T.,
Hirokawa, N.,
and Hall, A.
(1998)
EMBO J.
17,
149-158
27.
Suetsugu, S.,
Miki, H.,
and Takenawa, T.
(1998)
EMBO J.
17,
6516-6526
28.
Machesky, L. M.,
and Insall, R. H.
(1998)
Curr. Biol.
8,
1347-1356
29.
Rohatgi, R.,
Ma, L.,
Miki, H.,
Lopez, M.,
Kirchhausen, T.,
Takenawa, T.,
and Kirschner, M. W.
(1999)
Cell
97,
221-231
30.
Aspenstrom, P.,
Lindberg, U.,
and Hall, A.
(1996)
Curr. Biol.
6,
70-75
31.
Coso, O. A.,
Chiariello, M., Yu, J. C.,
Teramoto, H.,
Crespo, P.,
Xu, N.,
Miki, T.,
and Gutkind, J. S.
(1995)
Cell
81,
1137-1146
32.
Abdul-Manan, N.,
Aghazadeh, B.,
Liu, G. A.,
Majumdar, A.,
Ouerfelli, O.,
Siminovitch, K. A.,
and Rosen, M. K.
(1999)
Nature
399,
379-383
33.
Mott, H. R.,
Owen, D.,
Nietlispach, D.,
Lowe, P. N.,
Manser, E.,
Lim, L.,
and Laue, E. D.
(1999)
Nature
399,
384-388
34.
Minden, A.,
Lin, A.,
Claret, F. X.,
Abo, A.,
and Karin, M.
(1995)
Cell
81,
1147-1157
35.
Osada, S.,
Izawa, M.,
Koyama, T.,
Hirai, S.,
and Ohno, S.
(1997)
FEBS Lett.
404,
227-233
36.
Nur-E-Kamal, M.,
Kamal, J.,
Qureshi, M.,
and Maruta, H.
(1999)
Oncogene
18,
7787-7793
37.
Erickson, C. A.,
and Trinkaus, J. P.
(1976)
Exp. Cell Res.
99,
375-384
38.
Cunnignham, C. C.
(1995)
J. Cell Biol.
129,
1589-1599
39.
Trinkaus, J. P.
(1980)
Prog. Clin. Biol. Res.
41,
887-906
40.
Keller, H.,
and Eggli, P.
(1998)
Cell Motil. Cytoskeleton
41,
181-193
41.
Cunningham, C. C.,
Gorlin, J. B.,
Kwiatkowski, D. J.,
Hartwig, J. H.,
Janmey, P. A.,
Byers, H. R.,
and Stossel, T. P.
(1992)
Science
255,
325-327
42.
Mills, J. C.,
Stone, N. L.,
Erhardt, J.,
and Pittman, R. N.
(1998)
J. Cell Biol.
140,
627-636
43.
Huot, J.,
Houle, F.,
Rousseau, S.,
Deschesnes, R. G.,
Shah, G. M.,
and Landry, J.
(1998)
J. Cell Biol.
143,
1361-1373
44.
Fraser, I. D.,
Tavalin, S. J.,
Lester, L. B.,
Langeberg, L. K.,
Westphal, A. M.,
Dean, R. A.,
Marrion, N. V.,
and Scott, J. D.
(1998)
EMBO J.
17,
2261-2272
45.
Gray, P. C.,
Tibbs, V. C.,
Catterall, W. A.,
and Murphy, B. J.
(1997)
J. Biol. Chem.
272,
6297-6302
46.
Tibbs, V. C.,
Gray, P. C.,
Catterall, W. A.,
and Murphy, B. J.
(1998)
J. Biol. Chem.
273,
25783-25788
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
X-j Luo, H-b Diao, J-k Wang, H Zhang, Z-m Zhao, and B Su Association of haplotypes spanning PDZ-GEF2, LOC728637 and ACSL6 with schizophrenia in Han Chinese J. Med. Genet., December 1, 2008; 45(12): 818 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Nilsson, P. Eden, E. Olsson, R. Mansson, I. Astrand-Grundstrom, B. Strombeck, K. Theilgaard-Monch, K. Anderson, R. Hast, E. Hellstrom-Lindberg, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes Blood, October 15, 2007; 110(8): 3005 - 3014. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Navratil, J. G. Knoll, J. D. Whitesell, S. A. Tobet, and C. M. Clay Neuroendocrine Plasticity in the Anterior Pituitary: Gonadotropin-Releasing Hormone-Mediated Movement in Vitro and in Vivo Endocrinology, April 1, 2007; 148(4): 1736 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Giacomini, S. Y. Leung, X. Chen, S. T. Yuen, Y. H. Kim, E. Bair, and J. R. Pollack A Gene Expression Signature of Genetic Instability in Colon Cancer Cancer Res., October 15, 2005; 65(20): 9200 - 9205. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Ching, A. E. Kisailus, and P. D. Burbelo The Role of SPECs, Small Cdc42-binding Proteins, in F-actin Accumulation at the Immunological Synapse J. Biol. Chem., June 24, 2005; 280(25): 23660 - 23667. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. de Toledo, F. Senic-Matuglia, J. Salamero, G. Uze, F. Comunale, P. Fort, and A. Blangy The GTP/GDP Cycling of Rho GTPase TCL Is an Essential Regulator of the Early Endocytic Pathway Mol. Biol. Cell, December 1, 2003; 14(12): 4846 - 4856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Peck, M. Oberst, K. B. Bouker, E. Bowden, and P. D. Burbelo The RhoA-binding protein, Rhophilin-2, Regulates Actin Cytoskeleton Organization J. Biol. Chem., November 8, 2002; 277(46): 43924 - 43932. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Serebriiskii, O. Mitina, E. N. Pugacheva, E. Benevolenskaya, E. Kotova, G. G. Toby, V. Khazak, W. G. Kaelin, J. Chernoff, and E. A. Golemis Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets Genome Res., November 1, 2002; 12(11): 1785 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Gladfelter, J. J. Moskow, T. R. Zyla, and D. J. Lew Isolation and Characterization of Effector-Loop Mutants of CDC42 in Yeast Mol. Biol. Cell, May 1, 2001; 12(5): 1239 - 1255. [Abstract] [Full Text] |
||||
![]() |
D. S. Hirsch, D. M. Pirone, and P. D. Burbelo A New Family of Cdc42 Effector Proteins, CEPs, Function in Fibroblast and Epithelial Cell Shape Changes J. Biol. Chem., January 5, 2001; 276(2): 875 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Richnau and P. Aspenstrom RICH, a Rho GTPase-activating Protein Domain-containing Protein Involved in Signaling by Cdc42 and Rac1 J. Biol. Chem., September 7, 2001; 276(37): 35060 - 35070. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Reeder, I. G. Serebriiskii, E. A. Golemis, and J. Chernoff Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants That Selectively Couple to Cdc42 J. Biol. Chem., October 26, 2001; 276(44): 40606 - 40613. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||